Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis

• Autor(a) principal: Ayres,Eveline da Cruz Boa Sorte
• Data de Publicação: 2022
• Outros Autores: Dias,Álvaro Felipe de Lima Ruy, Monteiro,Bruna Ribeiro Gomes, Pazzini,Sarah Szimanski, Barbosa,Mateus Elias Chagas, Silva,Eveliny Barroso da, Macedo,Luis Felipe da Cruz, Sousa,Valéria Régia Franco, Dutra,Valéria, Nakazato,Luciano, Almeida,Arleana do Bom Parto Ferreira de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Brasileira de Parasitologia Veterinária (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-29612022000300305
• topic: Miltefosine; Allopurinol; Leishmania infantum; qPCR; skin

Abstract Canine visceral leishmaniasis is an endemic zoonosis in Brazil. Dogs are the main hosts in urban environments. The treatment has gained popularity since the Brazilian government authorized miltefosine for canine treatment. The aim of this study was to investigate the clinical and parasitological impact of short-term treatment with miltefosine and allopurinol, alone and in combination. We evaluated the ability of pharmacotherapy to reduce clinical signs of disease, antibody levels using the indirect fluorescence antibody test (IFAT) and skin parasite load via qPCR after 28 days of treatment. The therapeutic protocols promoted a significant decline in clinical signs and in the skin parasite load in dogs (p < 0.01). We observed a moderate correlation between the skin parasite load and the clinical score in all three treatment groups (r > 0.5) Antibody levels did not decrease in this short period. It was concluded that the treatment with allopurinol reduced the number of parasites in the skin of dogs with visceral leishmaniasis in the short term. However, its efficiency is potentiated when associated with miltefosine.